Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). (Q35557832)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 May 2011

Language	Label	Description	Also known as
English	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).	scientific article published on 13 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1 reference

based on heuristic

inferred from title

28

object named as

Roland Veelken

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Rebecca Fischer-Betz

11

object named as

Rebecca Fischer-Betz

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ulf Müller-Ladner

17

object named as

Ulf Müller-Ladner

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Andrea Rubbert-Roth

13

object named as

Andrea Rubbert-Roth

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Bernd C Kieseier

25

object named as

Bernd Kieseier

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

29

object named as

Ulf Ziemann

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

48

object named as

Heinz Wiendl

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Hans-Peter Tony

1

object named as

Hans-Peter Tony

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christof Specker

0 references

Michael Sticherling

27

object named as

Michael Sticherling

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

37

object named as

Rüdiger Eming

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

38

object named as

Michael Hertl

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Hendrik Schulze-Koops

3

object named as

Hendrik Schulze-Koops

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Gerd Burmester

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Mathias Grunke

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Joerg Henes

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ina Kötter

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Judith Haas

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Leonore Unger

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Svjetlana Lovric

9

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Marion Haubitz

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Gamal Chehab

12

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christof Specker

14

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jutta Weinerth

15

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Julia Holle

16

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ramona König

18

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christoph Fiehn

19

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Philip Burgwinkel

20

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Klemens Budde

21

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Helmut Sörensen

22

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Michael Meurer

23

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Martin Aringer

24

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Cornelia Erfurt-Berge

26

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Frank Strutz

30

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Praxis von Wussow

31

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Florian M P Meier

32

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Nico Hunzelmann

33

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Enno Schmidt

34

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Raoul Bergner

35

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Andreas Schwarting

36

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Rudolf Stadler

39

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Michael Schwarz-Eywill

40

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Siegfried Wassenberg

41

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Martin Fleck

42

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Claudia Metzler

43

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Uwe Zettl

44

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jens Westphal

45

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Stefan Heitmann

46

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Anna L Herzog

47

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Waltraud Jakob

49

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Elvira Schmidt

50

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Klaus Freivogel

51

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Thomas Dörner

52

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

GRAID investigators

53

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

13 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

R75

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B cells as therapeutic targets in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab in severe pemphigus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell-directed therapies for autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Mortality in systemic vasculitis: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab for severe refractory pediatric Wegener granulomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

A single cycle of rituximab for the treatment of severe pemphigus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Immune status and risk for infection in patients receiving chronic immunosuppressive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

The red wolf remains a wily foe.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab for peripheral ulcerative keratitis with wegener granulomatosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Prognosis and mortality of polymyositis and dermatomyositis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids

1 reference

https://api.crossref.org/works/10.1186%2FAR3337

21 January 2018

Rituximab may form a complex with iGmÎº mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virusâ induced vasculitis

1 reference

https://api.crossref.org/works/10.1186%2FAR3337

21 January 2018

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two cases of refractory Wegener's granulomatosis successfully treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in ANCA-associated disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Dimensions Publication ID

0 references

release_omthyp7bwnei3l2tkgtdwv3ngu

1 reference

https://api.fatcat.wiki/v0/release/omthyp7bwnei3l2tkgtdwv3ngu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35557832&oldid=2197475578"